{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HIV incidence": "0.20 per 100 person-years",
                    "95% CI": "0.06\u20130.52"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[0.20 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HIV incidence": "1.85 per 100 person-years",
                    "95% CI": "1.3\u20132.57"
                },
                "measures": "[HIV incidence]",
                "outcomes": "[1.85 per 100 person-years]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.20%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Overall",
                    "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                    "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                    "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.12, 0.05-0.31, <0.0001]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "<25 years",
                    "events per total PY": "20/851 (2.34%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.35%, 2.34%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "age": "\u226525 years",
                    "events per total PY": "16/1091 (1.47%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.09%, 1.47%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "DMPA",
                    "events per total PY": "21/1000 (2.10%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.30%, 2.10%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "NET-EN",
                    "events per total PY": "6/182 (3.30%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.57%, 3.30%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Implant",
                    "events per total PY": "8/607 (1.32%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.32%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Implant",
                    "events per total PY": "8/607 (1.32%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.32%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Implant",
                    "events per total PY": "8/607 (1.32%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.32%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Implant",
                    "events per total PY": "8/607 (1.32%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.32%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Implant",
                    "events per total PY": "8/607 (1.32%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.32%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Implant contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.06, 0.00-1.16]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Other",
                    "events per total PY": "1/152 (0.66%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 0.66%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Other",
                    "events per total PY": "1/152 (0.66%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 0.66%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Other",
                    "events per total PY": "1/152 (0.66%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 0.66%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Other",
                    "events per total PY": "1/152 (0.66%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 0.66%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "contraceptive method": "Other",
                    "events per total PY": "1/152 (0.66%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 0.66%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Other contraceptive method",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.32, 0.01-9.89]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "27/1447 (1.87%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0.29%, 1.87%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "cabotegravir",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "9/495 (1.82%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[0%, 1.82%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": "\u226430 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.87%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "analysis group": "TDF-FTC",
                    "body-mass index": ">30 kg/m<sup>2</sup>",
                    "events per total PY": "36/1942 (1.85%)"
                },
                "measures": "[events per total PY]",
                "outcomes": "[1.82%, 1.85%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.12 (0.05\u20130.31)",
                    "p value": "<0.0001"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.12 (0.05\u20130.31)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI >30 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "0",
                    "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                    "Method": "Firth's method used due to zero infections in cabotegravir group"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.05, 0.00-0.96]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.17 (0.05\u20130.54)",
                    "p value": "0.53"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.17 (0.05\u20130.54)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.09 (0.02\u20130.49)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.09 (0.02\u20130.49)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.16 (0.05\u20130.53)",
                    "p value": "0.47"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.16 (0.05\u20130.53)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.05 (0.00\u20130.96)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.05 (0.00\u20130.96)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.22 (0.03\u20131.48)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.22 (0.03\u20131.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.06 (0.00\u20131.16)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.06 (0.00\u20131.16)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age <25 years",
                    "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                    "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI, p value]",
                "outcomes": "[0.17, 0.05-0.54, 0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "Age \u226525 years",
                    "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                    "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.09, 0.02-0.49]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "DMPA contraceptive method",
                    "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                    "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.05-0.53]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "NET-EN contraceptive method",
                    "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                    "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.22, 0.03-1.48]"
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "study design": "ITT",
                    "primary endpoint definition": "HIV infections",
                    "HR": "Firth's method",
                    "HR (95% CI)": "0.32 (0.01\u20139.89)",
                    "p value": "0.87"
                },
                "measures": "[HR (95% CI)]",
                "outcomes": "[0.32 (0.01\u20139.89]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Subgroup": "BMI \u226430 kg/m\u00b2",
                    "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                    "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                    "Method": "Standard estimation method (no indication of zero infections)"
                },
                "measures": "[HR, 95% CI]",
                "outcomes": "[0.16, 0.06-0.45]"
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 37,
    "total_ground_truth_claims": 9,
    "number_of_matches": 4
}